ClariTrial | Search Clinical Trials

Explore/cancer oncology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

6,349 results for “cancer oncology” · Recruiting · Phase 3 · Phase 2

Page 1 of 424

Recruiting

DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

Phase 3Older PatientsColorectal CancerMetastatic Cancer

Doublet Chemotherapy, Standard Dose (100%)Doublet Chemotherapy, Dose-reduced (75%)Monotherapy, Standard Dose (100%)+1 more

Leiden University Medical Center587 participants36 sites · NetherlandsCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Phase 2Malignant Ovarian Epithelial TumorPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian Carcinoma

Akt/ERK Inhibitor ONC201PaclitaxelQuestionnaire Administration

Ira Winer62 participants2 sites · United StatesCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2Triple Negative Breast CancerBreast Cancer

Capecitabine

Stanford University40 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Phase 2Adenocarcinoma of the RectumLocally Advanced Rectal AdenocarcinomaRectal Adenocarcinoma

TrastuzumabTucatinib

Memorial Sloan Kettering Cancer Center37 participants7 sites · United StatesCompletes Jul 2027

Compare CT.gov Full analysis →

Recruiting

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Phase 3Non-Small Cell Lung Cancer

Lung SurgeryRadiation therapy

University of Texas Southwestern Medical Center272 participants50 sites · United States, Australia, CanadaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Radiotherapy Delivery in Deep Inspiration for Pediatric Patients

Phase 1Phase 2Pediatric Cancer

radiotherapy delivery in deep-inspiration

Copenhagen University Hospital, Rigshospitalet25 participants3 sites · Denmark, FinlandCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Durvalumab and Oleclumab in Resectable PDAC

Phase 2Pancreatic Ductal Adenocarcinoma

DurvalumabOleclumab

University Health Network, Toronto22 participants1 site · CanadaCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Phase 3Neuroendocrine Carcinoma

Standard of Care ChemotherapyTarlatamab

Intergroupe Francophone de Cancerologie Thoracique129 participants40 sites · FranceCompletes Feb 2029

Compare CT.gov Full analysis →

Recruiting

Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation

Phase 2Non-Small Cell Lung CancerRadiation Induced Lung Injury (RILI)

PentoxifyllinePlaceboα-Tocopherol

University Health Network, Toronto150 participants1 site · CanadaCompletes Nov 2031

Compare CT.gov Full analysis →

Recruiting

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Phase 2HER2-low Hormone Receptor Positive Breast Cancer

HLX22Trastuzumab Deruxtecan

Shanghai Henlius Biotech50 participants1 site · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Phase 2Advanced Breast Cancer

FulvestrantNeratinibAlpelisib+2 more

Dartmouth-Hitchcock Medical Center135 participants1 site · United StatesCompletes Oct 2030

Compare CT.gov Full analysis →

Recruiting

Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Phase 3Metastatic Microsatellite-stable Colorectal Cancer

Experimental drugControl Rx

Sun Yat-sen University176 participants12 sites · ChinaCompletes Jan 2026

Compare CT.gov Full analysis →

Recruiting

Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy

Phase 2Rectal Cancer

Dose escalated radiotherapy using a 1.5 T MR-Linac

University Hospital Tuebingen100 participants1 site · GermanyCompletes Jan 2029

Compare CT.gov Full analysis →

Recruiting

Study of How Safe and Effective Tarlatamab is in Brain Cancers

Phase 2Astrocytic TumorOligodendroglial Tumor

Tarlatamab

University Health Network, Toronto44 participants1 site · CanadaCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer

Phase 2Locally Advanced Esophageal or GE Junction Cancer

Hypofractionationcarboplatin + paclitaxel (CP)

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)60 participants7 sites · NetherlandsCompletes Apr 2028

Compare CT.gov Full analysis →

1–15 of 6,349

Explore/cancer oncology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

6,349 results for “cancer oncology” · Recruiting · Phase 3 · Phase 2

Page 1 of 424

Recruiting

DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

Phase 3Older PatientsColorectal CancerMetastatic Cancer

Doublet Chemotherapy, Standard Dose (100%)Doublet Chemotherapy, Dose-reduced (75%)Monotherapy, Standard Dose (100%)+1 more

Leiden University Medical Center587 participants36 sites · NetherlandsCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Phase 2Malignant Ovarian Epithelial TumorPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian Carcinoma

Akt/ERK Inhibitor ONC201PaclitaxelQuestionnaire Administration

Ira Winer62 participants2 sites · United StatesCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2Triple Negative Breast CancerBreast Cancer

Capecitabine

Stanford University40 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Phase 2Adenocarcinoma of the RectumLocally Advanced Rectal AdenocarcinomaRectal Adenocarcinoma

TrastuzumabTucatinib

Memorial Sloan Kettering Cancer Center37 participants7 sites · United StatesCompletes Jul 2027

Compare CT.gov Full analysis →

Recruiting

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Phase 3Non-Small Cell Lung Cancer

Lung SurgeryRadiation therapy

University of Texas Southwestern Medical Center272 participants50 sites · United States, Australia, CanadaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Radiotherapy Delivery in Deep Inspiration for Pediatric Patients

Phase 1Phase 2Pediatric Cancer

radiotherapy delivery in deep-inspiration

Copenhagen University Hospital, Rigshospitalet25 participants3 sites · Denmark, FinlandCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Durvalumab and Oleclumab in Resectable PDAC

Phase 2Pancreatic Ductal Adenocarcinoma

DurvalumabOleclumab

University Health Network, Toronto22 participants1 site · CanadaCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Phase 3Neuroendocrine Carcinoma

Standard of Care ChemotherapyTarlatamab

Intergroupe Francophone de Cancerologie Thoracique129 participants40 sites · FranceCompletes Feb 2029

Compare CT.gov Full analysis →

Recruiting

Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation

Phase 2Non-Small Cell Lung CancerRadiation Induced Lung Injury (RILI)

PentoxifyllinePlaceboα-Tocopherol

University Health Network, Toronto150 participants1 site · CanadaCompletes Nov 2031

Compare CT.gov Full analysis →

Recruiting

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Phase 2HER2-low Hormone Receptor Positive Breast Cancer

HLX22Trastuzumab Deruxtecan

Shanghai Henlius Biotech50 participants1 site · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Phase 2Advanced Breast Cancer

FulvestrantNeratinibAlpelisib+2 more

Dartmouth-Hitchcock Medical Center135 participants1 site · United StatesCompletes Oct 2030

Compare CT.gov Full analysis →

Recruiting

Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Phase 3Metastatic Microsatellite-stable Colorectal Cancer

Experimental drugControl Rx

Sun Yat-sen University176 participants12 sites · ChinaCompletes Jan 2026

Compare CT.gov Full analysis →

Recruiting

Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy

Phase 2Rectal Cancer

Dose escalated radiotherapy using a 1.5 T MR-Linac

University Hospital Tuebingen100 participants1 site · GermanyCompletes Jan 2029

Compare CT.gov Full analysis →

Recruiting

Study of How Safe and Effective Tarlatamab is in Brain Cancers

Phase 2Astrocytic TumorOligodendroglial Tumor

Tarlatamab

University Health Network, Toronto44 participants1 site · CanadaCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer

Phase 2Locally Advanced Esophageal or GE Junction Cancer

Hypofractionationcarboplatin + paclitaxel (CP)

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)60 participants7 sites · NetherlandsCompletes Apr 2028

Compare CT.gov Full analysis →

1–15 of 6,349